Señales en vivo de IGXT | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 may 2024 @ 15:59):

IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market...

Stats
Volumen de hoy	136 907
Volumen promedio	98 596.00
Capitalización de mercado	28.28M
EPS	$0 ( 2024-03-21 )
Próxima fecha de ganancias	( $0 ) 2024-05-07
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.70
ATR14	$0.00400 (2.47%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-19	Atai Life Sciences N.v.	Buy	0	Convertible Notes
2023-11-28	Atai Life Sciences N.v.	Buy	4 053 750	Warrant (Right to Buy)
2024-03-08	Atai Life Sciences N.v.	Buy	1 000 000	Convertible Notes
2023-10-06	Atai Life Sciences N.v.	Buy	8 500 000	Convertible Notes
2024-03-08	Atai Life Sciences N.v.	Buy	4 000 000	Warrant (Right to Buy)

INSIDER POWER
99.01
Last 94 transactions
Buy: 34 712 521 \| Sell: 605 000

IntelGenx Technologies Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

IntelGenx Technologies Finanzas

Annual	2023
Ingresos:	$1.04M
Beneficio Bruto:	$-1.46M (-140.52 %)
EPS:	$-0.0568

FY	2023
Ingresos:	$1.04M
Beneficio Bruto:	$-1.46M (-140.52 %)
EPS:	$-0.0568

FY	2022
Ingresos:	$950 000
Beneficio Bruto:	$-908 000 (-95.58 %)
EPS:	$-0.0726

FY	2021
Ingresos:	$1.54M
Beneficio Bruto:	$-721 000 (-46.97 %)
EPS:	$-0.0700

Financial Reports:

No articles found.

IntelGenx Technologies

IntelGenx Technologies Corp., a drug delivery company, focuses on the development and manufacturing of novel oral thin film products for the pharmaceutical market. It offers INT0008/2008, a Rizatriptan oral film product for the treatment of migraine; INT0046/2018 for adult use; INT0007/2006, an oral film product for treatment of erectile dysfunction; INT0043/2015, an oral film containing montelukast for treatment of Alzheimer; INT0027/2011 to treat opioid addition; INT0010/2006 for treatment of neuropathic pain and nausea in cancer patients undergoing chemotherapy; INT0036/2013, an oral film product for schizophrenia or bipolar 1 disorder; and INT0048/2020 for animal health. It is also developing INT0039/2013, INT0040/2014, INT0052/2020, INT0053/2020, and INT0054/2020. The company has licensing, development, and supply agreement with Tilray, Inc.; and development agreement with Cynapsus Therapeutics Inc. IntelGenx Technologies Corp. was founded in 2003 and is headquartered in Montreal, Canada.

Actualizaciones en tiempo real para IntelGenx Technologies [IGXT]

Upcoming Earnings Alert